One-fifth of all patients with pulmonary arterial hypertension suffer with the fatal disease for more than two years before being correctly diagnosed and properly treated, according to a new national study led by researchers at Intermountain Medical Center in Murray, Utah.
"For a lot of patients, that means the treatment is more difficult and the damage is irreversible," said Lynnette Brown, MD, PhD, a pulmonologist and researcher at Intermountain Medical Center and lead author of the study, which is published this week in the July issue of Chest, the journal of the American College of Chest Physicians.
"Finding out which patients are getting a delayed diagnosis is the first step in identifying them earlier, when treatment is easier and hopefully more effective," she said.
Pulmonary arterial hypertension (PAH) is a rare but fatal disease that occurs when small arteries in the lungs become narrowed and unable to carry as much blood as healthy arteries. Pressure builds as the heart works harder to move blood into the lungs. Eventually, the heart may fail.
Treatment options have improved, extending the lives of many patients. But treatment may be less effective for patients who receive a delayed diagnosis.
The study found that:
More than 21 percent of patients with PAH had symptoms for over two years before being diagnosed and beginning treatment.
Patients younger than 36 years old were most likely to receive a delayed diagnosis.
Patients who previously had been diagnosed with a common respiratory disorder such as obstructive airway disease or sleep apnea were also more likely to have a delayed diagnosis.
Dr. Brown and her colleagues gave several possible reasons for delayed diagnosis:Symptoms — shortness of breath, fatigue, swelling, and chest pain — can also point to more common disorders, such as asthma.
Younger patients make up one of the largest groups of uninsured Americans and therefore are less likely to seek early treatment.
Earlier diagnosis and treatment are vital, said Gregory Elliott, MD, chairman of the Department of Medicine at Intermountain Medical Center and another member of the research team.
"We have a lot more medications available to fight pulmonary arterial hypertension, but we can't use them all if we don't get to patients early enough in the course of the disease. If we can treat these patients sooner, we may find that we can improve survival," he said.
Researchers hope the study will give physicians more guidance in diagnosing pulmonary arterial hypertension.
"If a young person comes in complaining of shortness of breath, it’s alright to suspect something common. But if a patient is getting worse and not responding to treatment, it's time to look for something else," said Dr. Brown.
The study examined the medical records of 2,493 PAH patients from the national REVEAL registry (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management), including many of the 200 patients who are being treated at Intermountain Medical Center or University Hospital, the only hospitals in the Intermountain region capable of treating the complicated disease at an advanced stage.Co-authors were from the University of Utah; University of California, San Francisco; University of Pennsylvania; the Mayo Clinic; Boston University Medical Center; and Baylor College of Medicine.
Intermountain Medical Center serves as the flagship facility for the Intermountain Healthcare system.
Jess C. Gomez | EurekAlert!
Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University
New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.
But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...
Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.
The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
22.02.2018 | Life Sciences
22.02.2018 | Physics and Astronomy
22.02.2018 | Earth Sciences